Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages

AIDS Research and Human Retroviruses

Volumn 24, Issue 11, 2008, Pages 1399-1404

  Marsden, Matthew D ^a   Xu, Jie ^a   Hamer, Dean ^b   Zack, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOTOXIN; VIRUS ENVELOPE PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGIC FACTOR; PHORBOL ESTER; PROSTRATIN; UNCLASSIFIED DRUG;

ARTICLE; CELL KILLING; COLONY FORMING UNIT GM; EX VIVO STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; CELL CULTURE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; VIROLOGY;

ANTI-HIV AGENTS; CELLS, CULTURED; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; PHORBOL ESTERS;

EID: 57049168212     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0082     Document Type: Article

References (53)

1. Gunthard HF, Frost SDW, Leigh-Brown AJ, et al.: Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999;73:9404-9412.
2. Persaud D, Siberry GK, Ahonkhai A, et al.: Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004;78:968-979.
3. Ruff CT, Ray SC, Kwon P, et al.: Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002;76:9481-9492.
4. Chun T-W, Davey RT, Engel D, Lane HC, and Fauci AS: AIDS: Re-emergence of HIV after stopping therapy. Nature 1999;401:874-875.
5. Davey RT, Jr., Bhat N, Yoder C, et al.: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-15114.
6. Harrigana PR, Whaley M, and Montaner JSG: Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59-F62.
7. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
8. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
9. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
10. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
11. Laughlin MA, Zeichner S, Kolson D, et al.: Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 1993;196:496-505.
12. Popik W and Pitha PM: Role of tumor necrosis factor alpha in activation and replication of the tat-defective human immunodeficiency virus type 1. J Virol 1993;67:1094-1099.
13. Kulkosky J, Culnan DM, Roman J, et al.: Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001;98:3006-3015.
14. Folks TM, Justement J, Kinter A, Dinarello CA, and Fauci AS: Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987;238:800-802.
15. Scripture-Adams DD, Brooks DG, Korin YD, and Zack JA: Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002;76:13077-13082.
16. Berger EA, Moss B, and Pastan I: Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc Natl Acad Sci USA 1998;95:11511-11513.
17. Pastan I, Hassan R, FitzGerald DJ, and Kreitman RJ: Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-237.
18. Thrush GR, Lark LR, Clinchy BC, and Vitetta ES: Immunotoxins: An update. Annu Rev Immunol 1996;14:49-71.
19. Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-388.
20. Kreitman RJ, Wilson WH, Bergeron K, et al.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-247.
21. Amlot PL, Stone MJ, Cunningham D, et al.: A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993;82:2624-2633.
22. Pincus SH, Fang H, Wilkinson RA, Marcotte TK, Robinson JE, and Olson WC: In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J Immunol 2003;170:2236-2241.
23. Lueders KK, De Rosa SC, Valentin A, Pavlakis GN, Roederer M, and Hamer DH: A potent anti-HIV immunotoxin blocks spreading infection by primary HIV type 1 isolates in multiple cell types. AIDS Res Hum Retroviruses 2004;20:145-150.
24. Kennedy PE, Bera TK, Wang QC, et al.: Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: Enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J Leukoc Biol 2006;80:1175-1182.
25. Brooks DG, Hamer DH, Arlen PA, et al.: Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003;19:413-423.
26. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
27. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
28. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-191.
29. Gendelman HE, Orenstein JM, Martin MA, et al.: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988;167:1428-1441.
30. Orenstein JM, Meltzer MS, Phipps T, and Gendelman HE: Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: An ultrastructural study. J Virol 1988;62:2578-2586.
31. Stevenson M: HIV-1 pathogenesis. Nat Med 2003;9:853-860.
32. Crowe SM and Sonza S: HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: A further obstacle to eradication. J Leukoc Biol 2000;68:345-350.
33. Sonza S, Mutimer HP, Oelrichs R, et al.: Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS (London, England) 2001;15:17-22.
34. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, and Delfraissy JF: Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:114-119.
35. Gartner S, Markovits P, Markovitz DM, Betts RF, and Popovic M: Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 1986;256:2365-2371.
36. Koenig S, Gendelman HE, Orenstein JM, et al.: Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986;233:1089-1093.
37. Gonzalez-Scarano F and Martin-Garcia J: The neuropathogenesis of AIDS. Nat Rev Immunol 2005;5:69-81.
38. Adachi A, Gendelman HE, Koenig S, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
39. Chalfie M, Tu Y, Euskirchen G, Ward WW, and Prasher DC: Green fluorescent protein as a marker for gene expression. Science 1994;263:802-805.
40. Prasher DC, Eckenrode VK, Ward WW, Prendergast FG, and Cormier MJ: Primary structure of the Aequorea victoria green-fluorescent protein. Gene 1992;111:229-233.
41. de Wet JR, Wood KV, DeLuca M, Helinski DR, and Subramani S: Firefly luciferase gene: Structure and expression in mammalian cells. Mol Cell Biol 1987;7:725-737.
42. O'Brien WA, Koyanagi Y, Namazie A, et al.: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990;348:69-73.
43. Naldini L, Blomer U, Gage FH, Trono D, and Verma IM: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996;93:11382-11388.
44. Burns JC, Friedmann T, Driever W, Burrascano M, and Yee JK: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993;90:8033-8037.
45. Marsden MD and Zack JA: Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J Virol 2007;81:6146-6150.
46. Bera TK, Kennedy PE, Berger EA, Barbas CF, 3rd, and Pastan I: Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med 1998;4:384-391.
47. McHugh L, Hu S, Lee BK, et al.: Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J Biol Chem 2002;277:34383-34390.
48. Kedzierska K and Crowe SM: Cytokines and HIV-1: Interactions and clinical implications. Antivir Chem Chemother 2001;12:133-150.
49. O'Brien WA, Namazi A, Kalhor H, Mao SH, Zack JA, and Chen IS: Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol 1994;68:1258-1263.
50. Chun TW, Engel D, Mizell SB, et al.: Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-655.
51. Rowe JM, Andersen JW, Mazza JJ, et al.: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-462.
52. Pelchen-Matthews A, Kramer B, and Marsh M: Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol 2003;162:443-455.
53. Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, and Marsh M: In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol 2007;177:329-341.